This animal model study investigated whether intranasal administration of GHK peptide could reduce Alzheimer’s disease-related symptoms in 5xFAD transgenic mice, which exhibit amyloid pathology and cognitive decline. The researchers found that GHK peptide treatment attenuated both behavioral deficits and neuropathological features associated with Alzheimer’s disease in these mice. This is an animal model study and represents preclinical evidence that would require human clinical validation before any therapeutic applications could be considered.